Discontinued — last reported Q4 '25
Pfizer D&A increased by 0.5% to $1.23B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.1%, from $1.37B to $1.23B. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 7.1% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2015
Last reportedQ4 2025
How to read this metric
Higher levels often indicate significant recent capital investment or large historical acquisitions, while lower levels may suggest aging assets.
Detailed definition
Depreciation and amortization represent the systematic allocation of the cost of tangible and intangible assets over the...
Peer comparison
High in capital-intensive industries like healthcare and manufacturing; peers often report this as a significant non-cash drag on earnings.
Metric ID:
is_depreciation_and_amortizationHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $931.00M | $981.00M | $562.00M | $1.19B | $822.00M | $822.00M | $778.00M | $1.49B | $1.18B | $1.18B | $883.00M | $1.30B | $1.31B | $1.31B | $1.37B | $1.21B | $1.21B | $1.22B | $1.23B |
| QoQ Change | — | +5.4% | -42.7% | +111.2% | -30.7% | +0.0% | -5.4% | +91.1% | -20.4% | -0.4% | -25.1% | +47.2% | +0.5% | +0.4% | +4.2% | -11.4% | +0.0% | +1.0% | +0.5% |
| YoY Change | — | — | — | — | -11.7% | -16.2% | +38.4% | +25.3% | +44.0% | +43.4% | +13.5% | -12.6% | +10.4% | +11.3% | +54.8% | -6.8% | -7.3% | -6.8% | -10.1% |
Range$562.00M – $1.49B
CAGR+6.4%
Avg YoY Growth+11.3%
Median YoY Growth+10.4%
Current Streak3 quarters growth
Business Segments
| Segment | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $359.75M | $359.75M | $203.25M | $203.25M | $203.25M | $203.25M | $331.00M | $348.00M |
| Total | $981.00M | $562.00M | $1.19B | $822.00M | $822.00M | $778.00M | $1.21B | — |
D&A at Other Companies
Frequently Asked Questions
- What is Pfizer's d&a?
- Pfizer (PFE) reported d&a of $1.23B in Q4 2025.
- How has Pfizer's d&a changed year-over-year?
- Pfizer's d&a decreased by 10.1% year-over-year, from $1.37B to $1.23B.
- What is the long-term trend for Pfizer's d&a?
- Over 4 years (2021 to 2025), Pfizer's d&a has grown at a 7.1% compound annual growth rate (CAGR), from $3.70B to $4.87B.
- What does d&a mean?
- The non-cash expense that spreads the cost of physical and intangible assets over their useful life.